Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer

  • Sequeiros, Tamara|||0000-0002-0908-2263
  • Rigau, Marina|||0000-0002-1691-454X
  • Chiva, Cristina
  • Montes, Melania|||0000-0002-4268-6608
  • Garcia-Grau, Iolanda
  • García, Marta|||0000-0001-5155-4730
  • Diaz-Mercedes, Sherley|||0000-0002-8164-8639
  • Celma, Ana|||0000-0002-3128-3811
  • Bijnsdorp, Irene
  • Campos, Alexandre
  • Di Mauro, Primiano
  • Borrós, Salvador|||0000-0002-4003-0381
  • Reventós, Jaume
  • Doll, Andreas|||0000-0001-8965-8682
  • Paciucci, Rosanna|||0000-0001-5651-5933
  • Pegtel, Michiel
  • de Torres, Inés|||0000-0002-5495-9140
  • Sabidó, Eduard|||0000-0001-6506-7714
  • Morote Robles, Juan|||0000-0002-2168-323X
  • Olivan, Mireia|||0000-0002-8464-0827
Rapid and reliable diagnosis of prostate cancer (PCa) is highly desirable as current used methods lack specificity. In addition, identification of PCa biomarkers that can classify patients into high- and low-risk groups for disease progression at early stage will improve treatment decision-making. Here, we describe a set of protein-combination panels in urinary extracellular vesicles (EVs), defined by targeted proteomics and immunoblotting techniques that improve early non-invasive detection and stratification of PCa patients.We report a two-protein combination in urinary EVs that classifies benign and PCa patients (ADSV-TGM4), and a combination of five proteins able to significantly distinguish between high- and low-grade PCa patients (CD63-GLPK5-SPHM-PSA-PAPP). Proteins composing the panels were validated by immunohistochemistry assays in tissue microarrays (TMAs) confirming a strong link between the urinary EVs proteome and alterations in PCa tissues. Moreover, ADSV and TGM4 abundance yielded a high diagnostic potential in tissue and promising TGM4 prognostic power. These results suggest that the proteins identified in urinary EVs distinguishing high- and low grade PCa are a reflection of histological changes that may be a consequence of their functional involvement in PCa development. In conclusion, our study resulted in the identification of protein-combination panels present in urinary EVs that exhibit high sensitivity and specificity for PCa detection and patient stratification. Moreover, our study highlights the potential of targeted proteomic approaches-such as selected reaction monitoring (SRM)-as diagnostic assay for liquid biopsies via urinary EVs to improve diagnosis and prognosis of suspected PCa patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer

  • Colomer, Carlota
  • Margalef, Pol
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Vert, Anna
  • Pecharroman, Irene
  • Solé Font, Laura|||0000-0002-3195-0565
  • Gonzàlez-Farré, Mònica|||0000-0002-0653-0980
  • Alonso, Josune|||0000-0001-6783-5166
  • Montagut, Clara
  • Martinez-Iniesta, Maria
  • Bertran, Joan
  • Borràs, Eva|||0000-0002-3859-9907
  • Iglesias, Mar|||0000-0002-2274-4671
  • Sabidó, Eduard|||0000-0001-6506-7714
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Boulton, Simon J.
  • Espinosa, Lluis|||0000-0002-2897-4099
Phosphorylated IKKα(p45) is a nuclear active form of the IKKα kinase that is induced by the MAP kinases BRAF and TAK1 and promotes tumor growth independent of canonical NF-κB signaling. Insights into the sources of IKKα(p45) activation and its downstream substrates in the nucleus remain to be defined. Here, we discover that IKKα(p45) is rapidly activated by DNA damage independent of ATM-ATR, but dependent on BRAF-TAK1-p38-MAPK, and is required for robust ATM activation and efficient DNA repair. Abolishing BRAF or IKKα activity attenuates ATM, Chk1, MDC1, Kap1, and 53BP1 phosphorylation, compromises 53BP1 and RIF1 co-recruitment to sites of DNA lesions, and inhibits 53BP1-dependent fusion of dysfunctional telomeres. Furthermore, IKKα or BRAF inhibition synergistically enhances the therapeutic potential of 5-FU and irinotecan to eradicate chemotherapy-resistant metastatic human tumors in vivo. Our results implicate BRAF and IKKα kinases in the DDR and reveal a combination strategy for cancer treatment. Colomer et al. discover that IKKα kinase contributes to the chemo- and radio-resistance of cancer cells by facilitating ATM activation and DNA repair. BRAF inhibitors prevent damage-induced IKKα activation, leading to the attenuation of ATM signaling and DNA repair. IKKα depletion or BRAF inhibitors combined with 5-FU and irinotecan synergistically enhance the killing of patient-derived xenograft tumors.